24/7 Wall St. on MSN40m
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Investor's Business Daily on MSN22m
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback